Archives

  • August, 2025
    Vol. 1 No. 1 (2025)

    The inaugural issue of the Journal of Diabesity focuses on clinically relevant and real-world research at the intersection of obesity and diabetes. This issue features original survey-based investigations evaluating patient-reported outcomes related to commonly prescribed metabolic and gastrointestinal therapies, including empagliflozin discontinuation symptoms, real-world experiences with linaclotide, weight changes associated with rimegepant (Nurtec ODT), and comparative patient perspectives on glipizide and empagliflozin for type 2 diabetes management.

    In addition, this issue presents a case report describing severe gastrointestinal intolerance and hepatic granulomas associated with semaglutide therapy, highlighting the importance of post-marketing pharmacovigilance in the era of expanding GLP-1 receptor agonist use.

    Collectively, the articles emphasize real-world evidence, medication safety, patient adherence, and emerging adverse effects, establishing the journal’s commitment to advancing patient-centered metabolic research.

  • Journal of Diabesity

    Volume 1, Issue 2
    Vol. 1 No. 2 (2026)

    Volume 1, Issue 2 (January–June 2026) of the Journal of Diabesity marks the continuation of the journal’s inaugural volume following the successful publication of its first issue (July–December 2025). Building on the foundation established with four original research articles and one case report in Issue 1, this issue continues to advance high-quality, peer-reviewed scholarship in diabetes, obesity, and metabolic health. The journal remains committed to promoting evidence-based research, clinical insights, and translational studies relevant to researchers and clinicians worldwide.